scholarly journals Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary

2011 ◽  
Vol 32 (6) ◽  
pp. 678-687 ◽  
Author(s):  
Phillip J. Whiley ◽  
Lucia Guidugli ◽  
Logan C. Walker ◽  
Sue Healey ◽  
Bryony A. Thompson ◽  
...  
2010 ◽  
Vol 31 (6) ◽  
pp. E1484-E1505 ◽  
Author(s):  
Logan C. Walker ◽  
Phillip J. Whiley ◽  
Fergus J. Couch ◽  
Daniel J. Farrugia ◽  
Sue Healey ◽  
...  

1998 ◽  
Vol 90 (15) ◽  
pp. 1138-1145 ◽  
Author(s):  
S. R. Lakhani ◽  
J. Jacquemier ◽  
J. P. Sloane ◽  
B. A. Gusterson ◽  
T. J. Anderson ◽  
...  

2019 ◽  
Vol 40 (11) ◽  
Author(s):  
Yael Laitman ◽  
Tara M. Friebel ◽  
Drakoulis Yannoukakos ◽  
Florentia Fostira ◽  
Irene Konstantopoulou ◽  
...  

2004 ◽  
Vol 75 (4) ◽  
pp. 535-544 ◽  
Author(s):  
David E. Goldgar ◽  
Douglas F. Easton ◽  
Amie M. Deffenbaugh ◽  
Alvaro N.A. Monteiro ◽  
Sean V. Tavtigian ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Elisabeth Jarhelle ◽  
Hilde Monica Frostad Riise Stensland ◽  
Geir Åsmund Myge Hansen ◽  
Siri Skarsfjord ◽  
Christoffer Jonsrud ◽  
...  

AbstractFamilies with breast and ovarian cancer are often tested for disease associated sequence variants in BRCA1 and BRCA2. Pathogenic sequence variants (PVs) in these two genes are known to increase breast and ovarian cancer risks in females. However, in most families no PVs are detected in these two genes. Currently, several studies have identified other genes involved in hereditary breast and ovarian cancer (HBOC). To identify genetic risk factors for breast and ovarian cancer in a Norwegian HBOC cohort, 101 breast and/or ovarian cancer patients negative for PVs and variants of unknown clinical significance (VUS) in BRCA1/2 were screened for PVs in 94 genes using next-generation sequencing. Sixteen genes were closely scrutinized. Nine different deleterious germline PVs/likely pathogenic variants (LPVs) were identified in seven genes in 12 patients: three in ATM, and one in CHEK2, ERCC5, FANCM, RAD51C, TP53 and WRN. Additionally, 32 different VUSs were identified and these require further characterization. For carriers of PV/LPV in many of these genes, there are no national clinical management programs in Norway. The diversity of genetic risk factors possibly involved in cancer development show the necessity for more knowledge to improve the clinical follow-up of this genetically diverse patient group.


2010 ◽  
Vol 97 (1) ◽  
pp. S61
Author(s):  
Vallée Maxime ◽  
Fabienne Lesueur ◽  
Amanda Spurdle ◽  
Frans Hogervorst ◽  
David E Goldgar ◽  
...  

2019 ◽  
Vol 40 (10) ◽  
pp. 1781-1796 ◽  
Author(s):  
Tara M. Friebel ◽  
Irene L. Andrulis ◽  
Judith Balmaña ◽  
Amie M. Blanco ◽  
Fergus J. Couch ◽  
...  

1999 ◽  
Vol 91 (16) ◽  
pp. 1421-1422 ◽  
Author(s):  
F. Eisinger ◽  
J. Jacquemier ◽  
E. Charafe-Jauffret ◽  
M.-C. Rio ◽  
D. Birnbaum ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document